150 related articles for article (PubMed ID: 38462984)
1. Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.
Pietka G; De Lord C; Matthias G; Cheung B; Atwal S; Furtado M; Cullis J; Grey-Davies L; Narayanan S; McGregor A; Kilner M; Bosworth J; McMullin MF; Coats T; Parcharidou A; Cavenagh J; Byrne J; Iyengar S; Mohammed K; Cross N; Hubank M; Ribeiro S; Khorashad J; Wren D; O'Connor S; Taussig D
Br J Haematol; 2024 Apr; 204(4):1325-1334. PubMed ID: 38462984
[TBL] [Abstract][Full Text] [Related]
2. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
[TBL] [Abstract][Full Text] [Related]
3. [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
Zhang LJ; Shi YY; Chen Y; Deng Y; Ding YH; Li Z; Chen KK; Ding BH; Wang CL; Yu L; He ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1985-1990. PubMed ID: 33283730
[TBL] [Abstract][Full Text] [Related]
4. Unique ethnic features of
Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
[TBL] [Abstract][Full Text] [Related]
5. Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study.
Nann D; Rau A; Mahmutovic L; Steinhilber J; Meca V; Federmann B; Vogel W; Bonzheim I; Quintanilla-Martinez L; Fend F
Virchows Arch; 2023 Dec; 483(6):835-845. PubMed ID: 37610626
[TBL] [Abstract][Full Text] [Related]
6. Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort.
Diral E; Campochiaro C; Tomelleri A; Bergonzi GM; Pizzano U; Ponzoni M; Bongiovanni L; Ronchi P; Tresoldi C; Rigamonti S; Scarfò F; Latino GM; Rinaldi E; Bernardi M; Dagna L; Ciceri F
Front Immunol; 2024; 15():1354130. PubMed ID: 38333211
[TBL] [Abstract][Full Text] [Related]
7. Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance.
Fernandez-Pol S; Ma L; Ohgami RS; Arber DA
Mod Pathol; 2016 Sep; 29(9):996-1003. PubMed ID: 27255165
[TBL] [Abstract][Full Text] [Related]
8. Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
Ferrone CK; Wong H; Semenuk L; Werunga B; Snetsinger B; Zhang X; Zhang G; Lui J; Richard-Carpentier G; Crocker S; Good D; Hay AE; Quest G; Carson N; Feilotter HE; Rauh MJ
J Mol Diagn; 2021 Oct; 23(10):1292-1305. PubMed ID: 34365012
[TBL] [Abstract][Full Text] [Related]
9. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
11. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
Vobugari N; Heuston C; Lai C
Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
[TBL] [Abstract][Full Text] [Related]
13. The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.
Barcellini W
Expert Rev Hematol; 2017 Jul; 10(7):649-657. PubMed ID: 28586251
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
[TBL] [Abstract][Full Text] [Related]
15. Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis.
Karner K; George TI; Patel JL
Ann Lab Med; 2019 Nov; 39(6):509-514. PubMed ID: 31240877
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of somatic mutation in unexplained blood cytopenia.
Malcovati L; Gallì A; Travaglino E; Ambaglio I; Rizzo E; Molteni E; Elena C; Ferretti VV; Catricalà S; Bono E; Todisco G; Bianchessi A; Rumi E; Zibellini S; Pietra D; Boveri E; Camaschella C; Toniolo D; Papaemmanuil E; Ogawa S; Cazzola M
Blood; 2017 Jun; 129(25):3371-3378. PubMed ID: 28424163
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
Noy-Lotan S; Krasnov T; Dgany O; Jeison M; Yanir AD; Gilad O; Toledano H; Barzilai-Birenboim S; Yacobovich J; Izraeli S; Tamary H; Steinberg-Shemer O
Br J Haematol; 2021 May; 193(3):570-580. PubMed ID: 33368157
[TBL] [Abstract][Full Text] [Related]
19. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
[TBL] [Abstract][Full Text] [Related]
20. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
